Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics

Digitalis Ventures Appoints Misti Ushio as a Managing Partner

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 4, 2023 GMT
Dr. Misti Ushio (Photo: Business Wire)
Dr. Misti Ushio (Photo: Business Wire)

NEW YORK--(BUSINESS WIRE)--Jan 4, 2023--

Digitalis Ventures announced today that Misti Ushio, Ph.D. has joined the group as a Managing Partner. Dr. Ushio brings more than 25 years of leadership in venture capital, pharmaceuticals, and early-stage life science company building. Most recently, as CEO, she founded and built the cardiovascular-focused biotechnology company TARA Biosystems to its successful acquisition last year by Valo Health.

This press release features multimedia. View the full release here:

Dr. Misti Ushio (Photo: Business Wire)

Digitalis Ventures Founder and Managing Partner, Geoff Smith, stated, “We are delighted to welcome Misti to Digitalis Ventures as we continue to grow our global team with start-up, scale-up, and governance expertise in company building. Misti brings a wealth of leadership and scientific experience to the group and, as a managing partner, she will lead in both firm strategy and investment portfolio management at Digitalis Ventures.”


In October 2022, Digitalis Ventures closed its fourth fund totaling $300 million in commitments. The new capital will be invested in leading entrepreneurs and researchers developing breakthrough science and technology with the potential to transform patients’ lives.

Dr. Ushio commented, “I am ecstatic to join the firm and to work with its recognized investment leaders in life science, health technology, and animal health innovation. I look forward to applying my company building and investment experience to the effort of scaling Digitalis Ventures and the portfolio investments as they advance from start-up to growth companies.”

Earlier in her career, Dr. Ushio served as Chief Strategy Officer and Managing Director of Harris & Harris Group, where she invested in, and advised, life science companies helping them translate transformational science into commercially successful companies. Additionally, she held management roles at Merck & Company, where she developed vaccines and biologics products, and at Columbia University, where she oversaw the intellectual property of several scientific and engineering portfolios. Dr. Ushio holds a Ph.D. in Biochemical Engineering from University College London and a B.S. in Chemical Engineering from Johns Hopkins University.


About Digitalis Ventures

Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across the healthcare ecosystem with the goal of supporting them through multiple rounds of financing. Digitalis is based in New York City, with investors in Boston, Los Angeles, San Francisco, Gainesville, and Zurich.

View source version on

CONTACT: Erik Clausen

Managing Partner

CG Life

c +1-781-608-7091



SOURCE: Digitalis Ventures

Copyright Business Wire 2023.

PUB: 01/04/2023 08:30 AM/DISC: 01/04/2023 08:31 AM